Pipeline

Indication Next clinical phase Development lead
Phase 1 Phase 2 Phase 3
Sonelokimab
Psoriasis (phase 3 ready)
MoonLake
Sonelokimab
Hidradenitis Suppurativa (HS)
MoonLake
Sonelokimab
Psoriatic Arthritis (PsA)
MoonLake
Sonelokimab
Ankylosing Spondylitis (AS, or r-axSpA)
MoonLake

MoonLake sponsors innovative research and clinical trials globally, targeting inflammatory diseases with major unmet medical need where Sonelokimab has the potential to transform patient outcomes. Lead indications going into Phase II trials are hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis (or r-axSpA).

PLAQUE-TYPE PSORIASIS

Rapid and durable clinical response with no unexpected safety findings in a Phase 2b clinical study in moderate to severe plaque-type psoriasis

The investigational Nanobody® Sonelokimab has been assessed in a randomized, placebo-controlled, Phase 2b study in 313 patients with moderate to severe plaque-type psoriasis. Sonelokimab demonstrated a rapid and durable high level clinical response (Investigator Global Assessment of Clear or Almost Clear [IGA 0/1], Psoriasis Area and Severity Index [PASI] 90/100) in patients with moderate to severe plaque-type psoriasis, with no unexpected safety findings. The study highlights the promise of Sonelokimab in a number of chronic inflammatory diseases where IL-17A and IL-17F play a key role such as psoriasis, hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.

References: Papp KA, et al. Lancet. 2021; 397:1564-1575